Dr. Yury Popov's NIH-, industry- and private foundations funded laboratory's major research focus is on liver fibrosis/cirrhosis and its life-threatening sequelae. Specifically, his multidisciplinary team investigates the basic mechanisms of progression and regression of liver scarring, with the goal of the development of non-invasive diagnostic tools to measure these processes in the clinic, and novel therapies to prevent and reverse cirrhosis and its life-threatening complications such as primary liver cancers.

Julia Wattacheril, MD, MPH is an associate professor of medicine, clinician investigator and director of the Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) program at Columbia University Irving Medical Center. Her clinical and translational work spans the multidisciplinary care of MASLD patients at all stages of their disease to the investigation of rare genetic variants influencing the development and progression of MASLD before and after liver transplantation.

Dr. Stevan Gonzalez is the Medical Director of Liver Transplantation at the Annette C. and Harold C. Simmons Transplant Institute at Baylor Scott & White in Fort Worth, Texas. He has worked as a transplant hepatologist at Baylor University Medical Center in Dallas and Baylor Scott & White All Saints Medical Center in Fort Worth since 2008, and Medical Director of Liver Transplantation at Baylor in Fort Worth since 2015. He has served on the OPTN Living Donor Committee since 2019, currently as Chair.

Grace L. Guo, MBBS, PhD, FAASLD, is a professor in the Department of Pharmacology and Toxicology at the Ernest Mario School of Pharmacy in the Rutgers University. She received a MBBS degree from the West China University of Medical Science (Now the West China Medical Center of Sichuan University), and a PhD degree in Toxicology from the University of Kansa Medical Center. Her postdoctoral training was obtained from the NCI, NIH, with Dr. Frank Gonzalez. Dr. Guo has been a faculty in the University of Kansas Medical Center from 2004 to 2012 and in Rutgers University since 2012.

I'm an assistant professor at the Division of Gastroenterology and Hepatology, Indiana University. Main research area of interest: Steatotic Liver Disease, Cirrhosis, Natural History, and Clinical Trials.

Professor Newsome runs the metabolic services at the Liver Unit at King's College Hospital London which includes a large multi-disciplinary clinic for patients with non-alcoholic fatty liver disease (NAFLD). He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapies in NAFLD published in the Lancet and the NEJM. He is the Co-ordinating Investigator for several global NAFLD studies. He chaired the national guidelines for liver transplantation in NAFLD and sat on the NICE Guideline Development Group for NAFLD.

Denise Lo is a liver transplant surgeon and Associate Professor at Emory University School of Medicine.

Dr. David Mulligan, an acclaimed abdominal organ transplant surgeon from the Mayo Clinic in Arizona and former Chief of the Division of Transplantation and Immunology, director of the Yale-New Haven Transplantation Center (YNHTC), and Professor of Surgery at Yale School of Medicine, has moved to Reno, NV to help build a kidney and liver transplant program for Renown Health. He also perform living donor liver transplants at University of Washington in Seattle intermittently with their existing full time team.